Loading
OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.
TNFRSF4 (chromosome 1p36.33) encodes OX40, the receptor for OX40 ligand (TNFSF4) and a costimulatory molecule implicated in long-term T-cell immunity (UniProt P43489). OX40 ligation augments CD4 and CD8 T-cell clonal expansion, effector differentiation and survival, and in some cases abrogates the suppressive activity of regulatory T cells (Croft 2009, Immunol Rev). INBRX-106, a hexavalent OX40 agonist antibody, is in a phase 2/3 study with pembrolizumab in first-line PD-L1-high head and neck squamous cell carcinoma (NCT06295731).
In plain words · OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.
OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.
A TNF-receptor-superfamily costimulator induced on activated T cells; agonists need receptor clustering, which is why hexavalent formats are tried.
No product in this corpus aims at OX40 (TNFRSF4) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
First described 1994. Earliest sequence paper UniProt cites for the protein: Latza et al, Eur. J. Immunol, 1994, "The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen". Source.
Sources: HGNC HGNC:11918 (approved symbol, name, aliases and cross-references); UniProt P43489 (protein name, function and tissue specificity)
A TNF-receptor-superfamily costimulator induced on activated T cells; agonists need receptor clustering, which is why hexavalent formats are tried.
Query for this target: (TITLE:"OX40" OR ABSTRACT:"OX40" OR TITLE:"TNFRSF4" OR ABSTRACT:"TNFRSF4" OR TITLE:"CD134" OR ABSTRACT:"CD134" OR TITLE:"ACT35" OR ABSTRACT:"ACT35" OR TITLE:"TNF receptor superfamily member 4" OR ABSTRACT:"TNF receptor superfamily member 4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OX40 (TNFRSF4), not a curated reading list.
Shares CD137 (4-1BB, TNFRSF9), Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Pembrolizumab and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Pembrolizumab and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.